EyePoint, Inc (EYPT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $34.82M
Last updated: Nov 17, 2026 at 11:05 AM ET
EyePoint, Inc (EYPT) Earnings: Report Dates and Results
EyePoint (EYPT) is expected to report earnings on Mar 2, 2027. In the quarter ended Sep 30, 2026, EyePoint reported EPS of -$1.07, below the -$0.88 estimate. It beat the EPS estimate in 1 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
EYPT has an expected report date of Mar 2, 2027.
EYPT Earnings Call
The latest EYPT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, EYPT beat 15, missed 20 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $756000, down 21.7% from $966000 a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.07 | -$0.88 | -$1.19 - -$0.79 | -21.59% | Miss | N/A | 11 | 1 up, 2 down | Nov 4, 2026 | $756000 |
| Jun 30, 2026 | -$1.09 | -$0.92 | -$1.20 - -$0.77 | -18.48% | Miss | N/A | 12 | 0 up, 1 down | Aug 5, 2026 | $507000 |
| Mar 31, 2026 | -$0.99 | -$0.81 | -$0.89 - -$0.76 | -22.22% | Miss | N/A | 10 | N/A | May 6, 2026 | $696000 |
| Dec 31, 2025 | -$0.81 | -$0.75 | -$0.90 - -$0.61 | -8.33% | Miss | N/A | 9 | 1 up, 1 down | Mar 4, 2026 | $619000 |
| Sep 30, 2025 | -$0.85 | -$0.77 | -$0.94 - -$0.67 | -10.39% | Miss | N/A | 10 | 6 up, 3 down | Nov 5, 2025 | $966000 |
| Jun 30, 2025 | -$0.85 | -$0.80 | -$0.96 - -$0.55 | -6.25% | Miss | N/A | 12 | 1 up, 8 down | Aug 6, 2025 | $5.33M |
| Mar 31, 2025 | -$0.65 | -$0.69 | -$0.83 - -$0.63 | +5.80% | Beat | N/A | 10 | 0 up, 6 down | May 7, 2025 | $24.45M |
| Dec 31, 2024 | -$0.64 | -$0.48 | -$0.64 - -$0.31 | -34.31% | Miss | N/A | 11 | 3 up, 0 down | Mar 5, 2025 | $11.59M |
| Sep 30, 2024 | -$0.54 | -$0.54 | -$0.69 - -$0.40 | 0.00% | In line | N/A | 12 | 1 up, 0 down | Nov 7, 2024 | $10.52M |
| Jun 30, 2024 | -$0.58 | -$0.51 | -$0.66 - -$0.34 | -13.73% | Miss | N/A | 10 | 0 up, 0 down | Aug 7, 2024 | $9.48M |
| Mar 31, 2024 | -$0.55 | -$0.42 | -$0.63 - -$0.30 | -30.95% | Miss | N/A | 10 | 1 up, 0 down | May 8, 2024 | $11.68M |
| Dec 31, 2023 | -$0.33 | -$0.49 | -$0.76 - -$0.29 | +32.65% | Beat | N/A | 11 | 0 up, 0 down | Mar 7, 2024 | $14.03M |
| Sep 30, 2023 | -$0.33 | -$0.51 | -$0.70 - -$0.39 | +35.29% | Beat | N/A | 7 | 0 up, 0 down | Nov 1, 2023 | $15.20M |
| Jun 30, 2023 | -$0.61 | $0.37 | -$0.72 - $1.52 | -264.86% | Miss | N/A | 8 | 1 up, 0 down | Aug 2, 2023 | $9.11M |
| Mar 31, 2023 | -$0.56 | -$0.65 | -$0.75 - -$0.62 | +13.85% | Beat | N/A | 6 | 0 up, 0 down | May 3, 2023 | $7.68M |
| Dec 31, 2022 | -$1.16 | -$0.61 | -$0.67 - -$0.57 | -90.16% | Miss | N/A | 6 | 0 up, 0 down | Mar 2, 2023 | $10.53M |
| Sep 30, 2022 | -$0.49 | -$0.69 | -$0.79 - -$0.63 | +28.99% | Beat | N/A | 5 | 0 up, 0 down | Nov 2, 2022 | $10.01M |
| Jun 30, 2022 | -$0.52 | -$0.55 | -$0.59 - -$0.46 | +5.45% | Beat | N/A | 6 | 0 up, 0 down | Aug 3, 2022 | $11.56M |
| Mar 31, 2022 | -$0.52 | -$0.59 | -$0.64 - -$0.50 | +11.86% | Beat | N/A | 5 | 0 up, 0 down | May 4, 2022 | $9.29M |
| Dec 31, 2021 | -$0.59 | -$0.53 | -$0.59 - -$0.41 | -11.32% | Miss | N/A | 4 | N/A | Mar 3, 2022 | $11.54M |
| Sep 30, 2021 | -$0.58 | -$0.40 | -$0.47 - -$0.36 | -45.00% | Miss | N/A | 5 | 2 up, 0 down | Nov 3, 2021 | $9.06M |
| Jun 30, 2021 | -$0.42 | -$0.45 | -$0.52 - -$0.30 | +6.67% | Beat | N/A | 6 | N/A | Aug 4, 2021 | $9.01M |
| Mar 31, 2021 | -$0.50 | -$0.50 | -$0.54 - -$0.35 | 0.00% | In line | N/A | 5 | N/A | May 5, 2021 | $7.32M |
| Dec 31, 2020 | -$1.00 | -$0.17 | -$0.81 - $0.46 | -488.24% | Miss | N/A | 5 | N/A | Mar 4, 2021 | $41.57M |
| Sep 30, 2020 | -$0.30 | -$0.30 | -$0.90 - -$0.10 | 0.00% | In line | N/A | 4 | N/A | Nov 5, 2020 | $15.70M |
| Jun 30, 2020 | -$1.00 | -$1.05 | -$1.20 - -$0.90 | +4.76% | Beat | N/A | 4 | N/A | Aug 5, 2020 | $4.12M |
| Mar 31, 2020 | -$1.10 | -$0.95 | -$1.10 - -$0.80 | -15.79% | Miss | N/A | 4 | N/A | May 6, 2020 | $7.49M |
| Dec 31, 2019 | -$1.00 | -$1.17 | -$1.30 - -$1.10 | +14.53% | Beat | N/A | 3 | N/A | Mar 5, 2020 | $8.63M |
| Sep 30, 2019 | -$1.50 | -$1.37 | -$1.50 - -$1.20 | -9.49% | Miss | N/A | 4 | N/A | Nov 7, 2019 | $2.51M |
| Jun 30, 2019 | -$1.10 | -$1.20 | N/A | +8.33% | Beat | N/A | 2 | N/A | Aug 7, 2019 | $7.21M |
| Mar 31, 2019 | -$1.60 | -$1.37 | -$1.60 - -$0.90 | -16.79% | Miss | N/A | 3 | N/A | May 8, 2019 | $2.01M |
| Dec 31, 2018 | -$1.20 | -$1.40 | -$1.50 - -$1.30 | +14.29% | Beat | N/A | 2 | N/A | Mar 14, 2019 | $2.44M |
| Sep 30, 2018 | -$1.90 | -$1.47 | -$2.20 - -$1.10 | -29.25% | Miss | N/A | 3 | N/A | Nov 6, 2018 | $486000 |
| Jun 30, 2018 | -$1.89 | -$1.40 | -$1.40 - -$0.80 | -35.00% | Miss | N/A | 3 | N/A | Sep 12, 2018 | $1.16M |
| Mar 31, 2018 | -$1.02 | -$1.20 | -$1.50 - -$1.10 | +15.00% | Beat | N/A | 4 | N/A | May 8, 2018 | $486000 |
| Dec 31, 2017 | -$1.30 | -$1.50 | N/A | +13.33% | Beat | N/A | N/A | N/A | Feb 7, 2018 | $933000 |
| Sep 30, 2017 | -$1.50 | -$1.50 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 7, 2017 | $385000 |
| Jun 30, 2017 | -$1.60 | -$1.50 | N/A | -6.67% | Miss | N/A | N/A | N/A | Sep 11, 2017 | $701000 |
| Mar 31, 2017 | -$1.50 | -$1.50 | N/A | 0.00% | In line | N/A | N/A | N/A | May 4, 2017 | $590000 |
| Dec 31, 2016 | $0.00 | -$1.83 | N/A | +99.89% | Beat | N/A | N/A | N/A | Feb 7, 2017 | $5.97M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.16, after -$2.31 the year before. It was -$5.50 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.16 | N/A |
| Dec 31, 2024 | -$2.31 | N/A |
| Dec 31, 2023 | -$1.83 | N/A |
| Dec 31, 2022 | -$2.69 | N/A |
| Dec 31, 2021 | -$2.09 | N/A |
| Dec 31, 2020 | -$3.40 | N/A |
| Dec 31, 2019 | -$5.20 | N/A |
| Dec 31, 2018 | -$6.01 | N/A |
| Dec 31, 2017 | -$5.90 | N/A |
| Dec 31, 2016 | -$5.50 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,300 words across 15 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,297 | 15 | |
| 2026Q1 | Mar 31, 2026 | 5,549 | 14 | |
| 2025Q4 | Dec 31, 2025 | 7,084 | 15 | |
| 2025Q3 | Sep 30, 2025 | 4,322 | 8 | |
| 2025Q2 | Jun 30, 2025 | 6,496 | 15 | |
| 2025Q1 | Mar 31, 2025 | 7,047 | 17 | |
| 2024Q4 | Dec 31, 2024 | 7,187 | 15 |
2026Q3 Earnings Call
Opening remarks
George Elston CFO Thank you, and thank you all for joining us on today's conference call to discuss EyePoint's third quarter 2026 financial results and recent corporate developments. With me today is Dr. Jay Duker, President and Chief Executive Officer of EyePoint. Jay will begin with a review of recent corporate updates and discuss our clinical program for DURAVYU in DME and the results from the wet AMD program. I will close with commentary on the third quarter 2026 financial results. We will then open the call for your questions, where we will be joined by Dr. Ramiro Ribeiro, our Chief Medical Officer; Mike Campbell, our Chief Commercial Officer; and Dr. Tarek Hassan, our Chief Strategic Science Officer. Earlier this morning, we issued a press release detailing our financial results and recent corporate developments. A copy of the release can be found in the Investor Relations tab on the company website, www.eyepoint.bio. Before we begin our formal comments, I'll remind you that various remarks we make today constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. These include statements about our future expectations, clinical developments and regulatory matters and timelines, the potential success of our products and product candidates, financial projections, and our plans and prospects. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent annual report on Form 10-K, which is on file with the SEC, and in other filings that we have made or may make with the SEC in the future. Any forward-looking statements represent our views as of today only. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change. Therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today. I'll now turn the call over to Dr. Jay Duker, President and Chief Executive Officer of EyePoint.
Jay Duker CEO Thank you, George. Good morning, everyone, and thank you for joining us. This has been an eventful quarter for EyePoint, and I want to begin with what is top of mind for all of us. This past August and October, we announced that our two Phase III wet AMD clinical trials did not meet the primary endpoint in the full analysis population. We are deeply disappointed with this result. At the same time, these two studies generated important clinical findings about DURAVYU.
Frequently Asked Questions About EYPT
When is EyePoint's next earnings date?
EyePoint's next earnings report is expected for Mar 2, 2027.
Did EYPT beat earnings estimates last quarter?
No. EyePoint reported EPS of -$1.07 for the quarter ended Sep 30, 2026, below the -$0.88 estimate by 21.59%.
What EPS do analysts expect from EYPT next quarter?
The consensus EPS estimate for EyePoint for the quarter ending Dec 31, 2026 is -$0.69 from 15 analysts, with estimates from -$0.91 to -$0.38.
How often does EYPT beat earnings estimates?
EyePoint beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -14.47%.
EYPT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors